NYSE - Nasdaq Real Time Price USD

Novo Nordisk A/S (NVO)

Compare
135.14 -1.83 (-1.34%)
As of 12:39 PM EDT. Market Open.
Loading Chart for NVO
DELL
  • Previous Close 136.97
  • Open 135.24
  • Bid 135.33 x 900
  • Ask 135.38 x 800
  • Day's Range 134.62 - 135.72
  • 52 Week Range 86.96 - 148.15
  • Volume 1,043,413
  • Avg. Volume 4,065,253
  • Market Cap (intraday) 596.819B
  • Beta (5Y Monthly) 0.13
  • PE Ratio (TTM) 45.05
  • EPS (TTM) 3.00
  • Earnings Date Nov 6, 2024
  • Forward Dividend & Yield 1.45 (1.06%)
  • Ex-Dividend Date Aug 16, 2024
  • 1y Target Est 149.53

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

www.novonordisk.com

69,260

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NVO

View More

Performance Overview: NVO

Trailing total returns as of 8/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NVO
32.07%
OMX Copenhagen 25 Index
7.84%

1-Year Return

NVO
46.57%
OMX Copenhagen 25 Index
11.30%

3-Year Return

NVO
171.08%
OMX Copenhagen 25 Index
1.20%

5-Year Return

NVO
452.36%
OMX Copenhagen 25 Index
72.98%

Compare To: NVO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NVO

View More

Valuation Measures

Annual
As of 8/23/2024
  • Market Cap

    604.91B

  • Enterprise Value

    604.08B

  • Trailing P/E

    45.64

  • Forward P/E

    39.84

  • PEG Ratio (5yr expected)

    2.45

  • Price/Sales (ttm)

    15.90

  • Price/Book (mrq)

    36.26

  • Enterprise Value/Revenue

    15.72

  • Enterprise Value/EBITDA

    30.28

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    34.84%

  • Return on Assets (ttm)

    22.80%

  • Return on Equity (ttm)

    88.57%

  • Revenue (ttm)

    258B

  • Net Income Avi to Common (ttm)

    89.9B

  • Diluted EPS (ttm)

    3.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    62.65B

  • Total Debt/Equity (mrq)

    50.71%

  • Levered Free Cash Flow (ttm)

    54.49B

Research Analysis: NVO

View More

Company Insights: NVO

Research Reports: NVO

View More

People Also Watch